Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Clinical trial NCT01019395 · COMPLETED
Trial details
- NCT number
- NCT01019395
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-01-05
- Primary completion
- 2012-03-20
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.